Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Archive — January 2025
Page 4 of 5 of this archive, newest first.
What changed at GL Biochem in January, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Everything a buyer assumes has been checked, ranked by whether it has
The absences are not concealment. They are the form the trade settled on, and no buyer has ever objected.
Holidays, surgery, sickness: interruption in practice
Supply interruption is the commonest cause of unplanned re-titration in this market, and it is almost never framed that way.
What a 32% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
South Africa caps tirzepatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to New Zealand after 3 consecutive customs detentions
The route did not close because of a rule about peptides.
At 214 nanometres you see every peptide bond. At 280 you see three residues.
Area per cent silently assumes that every species in the sample absorbs as strongly per unit mass as the parent. For peptide impurities that assumption is usually wrong, and…
When to stop escalating and when to stop entirely
We set out the questions that distinguish a symptom to manage from a dose to change.
FGP declines, for the 15th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Japan declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Inspectors cite Halvard & Pike Apothecary of Portland, Maine over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The change that weighs nothing at all
Deamidation adds 0.98 daltons. On a low-resolution instrument at incretin molecular weights, that is inside the noise.
Percentage of loss, absolute kilograms, and the sleight of hand between them
The trials measured mass. Nobody measured whether the participants got weaker.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.
The consolidator trading as Meridian Freight Partners closes after 21 years
A proper account of an operation that existed, and of what closing it cost.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 6 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The question no chromatogram has ever answered
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Denmark health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
Shenzhen export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
What the new Denmark guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The empty half of every certificate of analysis
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
The one randomised trial that combined an incretin with supervised exercise
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
Calder Vale Peptides of Skipton closes after 24 years
A proper account of an operation that existed, and of what closing it cost.
France caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
STEP 2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Canada pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Three services, one lot, and a spread of two and a half points
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Dual, triple, co-formulated: a taxonomy the coverage keeps collapsing
The glucagon arm raises energy expenditure and also raises hepatic glucose output. Balancing those is the whole engineering problem.
TRIUMPH-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Medutest result on a Hangzhou dulaglutide lot lands 3.0 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
The 14-day notice: how a compounding wind-down works in Singapore
The document is four pages. Three of them are about dates.
The arithmetic behind every identity confirmation, worked in full
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
Hydration, protein and the two failures that compound each other
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
SURMOUNT-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.